2 Large-Cap Companies Worth Watching and 1 Encountering Challenges

Understanding Mega-Cap Stocks

Large-cap companies dominate their sectors and often possess significant competitive advantages due to their size. While this scale provides strong barriers against competition, it also means these firms have already maximized most of their current market opportunities. To continue growing, they must invest heavily in new ventures, which can be risky.

These complexities can challenge even experienced investors. That's why StockStory was created—to guide you toward companies with the potential for sustained earnings growth. With that in mind, let's examine two industry leaders with powerful growth engines and one whose prospects may be limited.

Consider Selling This Mega-Cap: GE Vernova (GEV)

GE Vernova (GEV)

Market Capitalization: $224.3 billion

GE Vernova (NYSE:GEV) emerged in 2023 as a spin-off from General Electric's energy division. The company specializes in designing, producing, and maintaining power generation equipment and grid solutions, aiming to help clients build dependable and eco-friendly electrical systems.

Why GE Vernova May Not Be a Good Bet

• Its massive size restricts growth compared to smaller rivals, as shown by its modest 3.6% annual revenue increase over the past four years.
• Gross margins are just 16.2%, indicating substantial production expenses.
• Consistent operating margin losses point to challenges in managing costs effectively.

GE Vernova shares are priced at $831.75, reflecting a forward price-to-earnings ratio of 60.2.

Two Mega-Cap Stocks Worth Watching

Broadcom (AVGO)

Market Capitalization: $1.59 trillion

Broadcom (NASDAQ:AVGO) originated as Hewlett Packard's semiconductor division and has grown into a diversified tech giant. Its business spans wireless communication, networking, data storage, and infrastructure software, including mainframes and cybersecurity.

Why Broadcom Stands Out

• Impressive annual revenue growth of 32.5% over the last two years, signaling increased market share.
• Its products are difficult to duplicate at scale, resulting in a leading gross margin of 76.5%.
• Broadcom generates substantial free cash flow, giving it flexibility to invest in expansion or reward shareholders.

Broadcom trades at $336.24 per share, with a forward P/E ratio of 25.6.

Amgen (AMGN)

Market Capitalization: $198.3 billion

Founded in 1980 at the dawn of the biotech era, Amgen (NASDAQ:AMGN) is a leading biotechnology firm focused on discovering, developing, and manufacturing innovative treatments for serious conditions such as cancer, osteoporosis, and autoimmune disorders.

What Makes Amgen Exceptional

• Amgen's annual revenue growth of 14.2% over the past two years surpasses industry averages, highlighting the value of its products.
• With $36.75 billion in revenue, Amgen benefits from economies of scale and strong negotiating power.
• Its robust free cash flow margin of 28.6% allows for consistent reinvestment or shareholder returns.

Amgen is currently priced at $368.37 per share, with a forward P/E of 16.8.

Our Favorite Growth Stocks

Don't Miss: Top 5 Growth Picks — The most successful stocks often share one trait: explosive revenue growth. Meta, CrowdStrike, and Broadcom were all flagged by our AI and delivered returns of 315%, 314%, and 455%, respectively.

Discover which five stocks are highlighted this month—absolutely free.

Past selections include well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, and lesser-known companies such as Tecnoglass, which delivered a 1,754% five-year return.